ABSTRACT NUMBER: FEGGETTER MEDAL FOR SENIOR TRAINEES (ST3+)_4 MAIN ABSTRACT TEXT Introduction Esophageal cancer is the seventh most common cancer worldwide with over 570,000 new cases annually. Its pathology is relatively less understood and due to its aggressive nature, the 5-year survival rate is 15–20%. Despite the advancement in diagnostics, intraoperative technology, oncological interventions, and…
Comparison of the histopathological regression after neoadjuvant FLOT versus ECX in resectable gastroesophageal adenocarcinoma
ABSTRACT NUMBER: FEGGETTER MEDAL FOR SENIOR TRAINEES (ST3+)_3 MAIN ABSTRACT TEXT Introduction Neoadjuvant chemotherapy (NAC) with the FLOT regimen is increasingly used in the treatment of resectable oesophagogastric cancer (OGC). Histopathological tumour regression (TRG) is associated with a prognostic benefit. There is paucity of data on whether pathological complete response (pCR) rates between FLOT and…
Risk factors associated with not receiving adjuvant chemotherapy for locally advanced oesophagogastric adenocarcinoma
ABSTRACT NUMBER: FEGGETTER MEDAL FOR SENIOR TRAINEES (ST3+)_2 MAIN ABSTRACT TEXT Introduction Perioperative chemotherapy is standard of care in the curative treatment of locally advanced oesophagogastric adenocarcinoma (OGA) in the UK. There is however large number of patients who don’t undergo adjuvant component of both of these perioperative regimens. This study aimed to investigate factors…
Upper airway immune dysfunction in otitis media with effusion (OME)
ABSTRACT NUMBER: FEGGETTER MEDAL FOR SENIOR TRAINEES (ST3+)_1 MAIN ABSTRACT TEXT Introduction Otitis media with effusion (OME; ‘glue ear’) is the most common cause of reversible hearing loss in developed countries. In the UK every year 24,000 children undergo surgery (grommets +/- adenoidectomy) for OME. Despite this, the mechanism by which adenoidectomy improves the resolution…